ALECTOR INC (ALEC)
US0144421072 - Common Stock
Overall ALEC gets a fundamental rating of 3 out of 10. We evaluated ALEC against 588 industry peers in the Biotechnology industry. The financial health of ALEC is average, but there are quite some concerns on its profitability. ALEC is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ALEC has reported negative net income.
In the past year ALEC has reported a negative cash flow from operations.
ALEC had negative earnings in each of the past 5 years.
In the past 5 years ALEC reported 4 times negative operating cash flow.
1.2 Ratios
The Return On Assets of ALEC (-20.98%) is better than 81.40% of its industry peers.
ALEC has a Return On Equity (-97.22%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.98% | ||
| ROE | -97.22% | ||
| ROIC | N/A |
ROA(3y)-14.12%
ROA(5y)-21.26%
ROE(3y)-57.15%
ROE(5y)-59.33%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ALEC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ALEC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALEC has more shares outstanding
The number of shares outstanding for ALEC has been increased compared to 5 years ago.
There is no outstanding debt for ALEC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -0.88, we must say that ALEC is in the distress zone and has some risk of bankruptcy.
ALEC has a Altman-Z score (-0.88) which is comparable to the rest of the industry.
There is no outstanding debt for ALEC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.88 |
ROIC/WACCN/A
WACC9.31%
2.3 Liquidity
ALEC has a Current Ratio of 3.18. This indicates that ALEC is financially healthy and has no problem in meeting its short term obligations.
ALEC has a worse Current ratio (3.18) than 64.85% of its industry peers.
A Quick Ratio of 3.18 indicates that ALEC has no problem at all paying its short term obligations.
The Quick ratio of ALEC (3.18) is worse than 63.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.18 | ||
| Quick Ratio | 3.18 |
3. Growth
3.1 Past
ALEC shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.73%.
The Revenue for ALEC has decreased by -27.46% in the past year. This is quite bad
The Revenue has been growing by 28.50% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)3.73%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q22.22%
Revenue 1Y (TTM)-27.46%
Revenue growth 3Y66.31%
Revenue growth 5Y28.5%
Revenue growth Q2Q5.49%
3.2 Future
Based on estimates for the next years, ALEC will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.49% on average per year.
ALEC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 23.37% yearly.
EPS Next Y-38.39%
EPS Next 2Y-7.89%
EPS Next 3Y4.55%
EPS Next 5Y16.49%
Revenue Next Year-32.34%
Revenue Next 2Y19.5%
Revenue Next 3Y35.26%
Revenue Next 5Y23.37%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ALEC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALEC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.89%
EPS Next 3Y4.55%
5. Dividend
5.1 Amount
ALEC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ALECTOR INC
NASDAQ:ALEC (4/26/2024, 7:00:00 PM)
After market: 5.25 0 (0%)5.25
+0.44 (+9.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap502.69M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.98% | ||
| ROE | -97.22% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.16
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.18 | ||
| Quick Ratio | 3.18 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)3.73%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-38.39%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-27.46%
Revenue growth 3Y66.31%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y